Hi all,
I am just following up the House of Representatives USA bill to allow MDMA and Psoliscobin to be authorised for use (see previous thread) I asked Ai their opinion.
Based on the search results, there are several potential positive impacts for Bioxyne (ASX: BXN) following the legalization of MDMA and psilocybin in the USA
Market Leadership: Bioxyne, through its subsidiary Breathe Life Sciences (BLS), has already secured Australia's first Good Manufacturing Practice (GMP) license for the production of psilocybin and MDMA. This positions the company as a pioneer in the field, potentially giving it a competitive advantage in the global market.
Expanded Export Opportunities: Bioxyne plans to register its psilocybin and MDMA capsules for export, targeting universities, clinical trials, and research groups globally. U.S. legalization would likely increase demand from American institutions, expanding Bioxyne's international market reach.
Increased Revenue Potential: The company has already shown significant revenue growth, with a 171% increase to $12.6m for H1 FY25 compared to the previous corresponding period3. Legalization in the U.S. could further boost this growth trajectory.
Scalable Manufacturing Capacity: Bioxyne has a highly scalable site and rapidly replicable pharmaceutical grade GMP manufacturing operations3. This infrastructure positions the company well to meet increased demand following U.S. legalization.
Summary
Legalization of MDMA and psilocybin in the U.S. would likely present a mix of opportunities and challenges for Bioxyne (ASX: BXN). The company stands to benefit from increased global demand and expanded research collaborations but may face heightened competition and operational pressures. Its existing licenses and strategic positioning give it a strong foundation to capitalize on these changes effectively.
My research though not infallible shows one USA Company capable of MDMA production but it hasn't passed the GMP hurdle yet.
As to Psilocybin it seems there is none.
Costs for BXN to set up a LLC in the USA approximately 40K USD.
The U.S. psychedelic mushroom market, which includes psilocybin, is expected to grow at a CAGR of 11.5% from 2025 to 2030. The market size is projected to reach $4.32 billion by 2030, starting from $2.25 billion in 2024. Based on this growth rate, the estimated revenue for psilocybin in 2027 would be approximately $3.3 billion.
The broader U.S. psychedelic drugs market, which includes MDMA, is projected to grow at a CAGR of 16.8% from 2025 to 2032. The market size is expected to increase from $4.51 billion in 2024 to $15.62 billion by 20323. While specific numbers for MDMA alone are not provided, it constitutes a significant portion of this market due to its therapeutic potential for PTSD and other mental health conditions.
Has anyone please the CEO email address so I can introduce myself and follow up on this USA near term futuristic venture .
Kpax
Add to My Watchlist
What is My Watchlist?
